Selux Diagnostics’ Test Platform for Antimicrobial Susceptibility Named Breakthrough Device

The FDA has designated Boston-based Selux Diagnostics’ Next Generation Phenotyping (NGP) platform to be a breakthrough device.

The phenotyping device can deliver rapid antimicrobial susceptibility test results from blood culture or sterile body fluid samples.

The Selux NGP device is currently under FDA review as part of the company’s rapid antimicrobial susceptibility test system for isolated bacterial colonies, the company said.